Pharmacological Implications of Adjusting Abnormal Fear Memory: Towards the Treatment of Post-Traumatic Stress Disorder.
Chen-Cheng LinYia-Ping LiuPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Post-traumatic stress disorder (PTSD) is a unique clinical mental abnormality presenting a cluster of symptoms in which patients primarily experience flashbacks, nightmares and uncontrollable thoughts about the event that triggered their PTSD. Patients with PTSD may also have comorbid depression and anxiety in an intractable and long-term course, which makes establishing a comprehensive treatment plan difficult and complicated. The present article reviews current pharmacological manipulations for adjusting abnormal fear memory. The roles of the central monoaminergic systems (including serotonin, norepinephrine and dopamine) within the fear circuit areas and the involvement of the hypothalamic-pituitary-adrenal (HPA) axis and glucocorticoid receptor (GR) are explored based on attempts to integrate current clinical and preclinical basic studies. In this review, we explain how these therapeutic paradigms function based on their connections to stages of the abnormal fear memory process from condition to extinction. This may provide useful translational interpretations for clinicians to manage PTSD.
Keyphrases
- social support
- posttraumatic stress disorder
- prefrontal cortex
- working memory
- end stage renal disease
- ejection fraction
- chronic kidney disease
- palliative care
- newly diagnosed
- mental health
- stem cells
- prognostic factors
- case report
- systematic review
- combination therapy
- uric acid
- cell therapy
- mesenchymal stem cells
- patient reported